An update on drug combinations for treatment of myeloma

Bibliography

• MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The medical research council working party for leukaemia in adults. Lancet 1992;25:200-5
   Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996;335:91-7
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy: long term results from a prospective randomised trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755-9
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma. Final results of the Phase III US Intergroup trial S9321. J Clin Oncol 2006;24:929-36
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1060-73
   Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Falco P, et al. Efficacy of low dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Haematol J 2004;5:318-24
   Web of Science ®Google Scholar
• Sidra G, Williams CD, Russell NH, et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006;91:862-63
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with myeloma. Haematol J 2004;5:112-17
   Web of Science ®Google Scholar
• Garcia-Sanz R, Gonzalez-Porras Jr, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma patients. Leukemia 2005;18:856-63
   Web of Science ®Google Scholar
• Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003;122:607-16
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Thomson K, D'sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005;129:763-70
   PubMed Web of Science ®Google Scholar
• Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-39
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisolone in refractory and relapsed myeloma. Eur J Haematol 2006;76:273-77
   PubMed Web of Science ®Google Scholar
• Hussein MA, Baz R, Srkalovic G, et al. Phase II study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006;81:889-95
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole DH, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2006;24:431-6
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide and dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated myeloma. J Clin Oncol 2003;21:16-19
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine–doxorubicin–dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9
   PubMed Web of Science ®Google Scholar
• Wu P, Davies FE, Horton C, et al. The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide–vincristine–doxorubicin–methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case matched analysis. Leuk Lymphoma 2006;47:2335-8
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J, Harousseau J, et al. Superiority of melphalan – prednisolone + thalidomide over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 2006;24:A1
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients treated with thalidomide. Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507-14
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Thalidomide therapy and deep vein thrombosis in myeloma. Mayo Clin Proc 2005;80:1549-51
   PubMed Web of Science ®Google Scholar
• Breikreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007;21:1294-9
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Rasmussen E, et al.Thalidomide and hematopoietic cell transplantation in myeloma. N Engl J Med 2006;354:1021-30
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signalling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells. Therapeutic implications. Blood 2002;99:4525-30
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al. A randomized Phase II study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvezky R, et al. Lenalidomide plus high dose dexamethasone provides improved survival compared to high dose dexamethasone for relapsed, refractory myeloma. Results of a North American Phase III study. J Clin Oncol 2006;24:A427
   Google Scholar
• Dimopoulos MA, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma. Results of a Phase III study (MM-010). Blood 2005;106:A6
   Web of Science ®Google Scholar
• Stadtmauer E, Weber D, Dimopolous M, et al. Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma. Blood 2006;108:A3552
   Google Scholar
• Morgan GJ, Wu P, Davies FE, et al. Lenalidomide in combination with cyclophosphamide and dexamethasone is an effective and well tolerated regimen for myeloma patients. Br J Haematol 2007;137:268-9
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam MA, et al.Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma safety and efficacy. Ann Oncol 2006;17:1766-71
   PubMed Web of Science ®Google Scholar
• Knop S, Gerecke C, Topp MS, et al. Lenalidomide (Revlimid™), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma – first results of a German multicenter Phase I/II trial. Blood 2006;108:A408
   Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander N, et al. A randomized Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide low dose dexamethasone in newly diagnosed multiple myeloma: a trial coordinated by the Eastern cooperative oncology group. Blood 2006;108:A799
   Google Scholar
• Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian multiple myeloma network. J Clin Oncol 2007;25(28):4459-65
   PubMed Web of Science ®Google Scholar
• Knight R, Delap RJ, Zeldis JB. Lenalidomide and venous thrombosis in myeloma. N Engl J Med 2006;354:2079-80
   PubMed Web of Science ®Google Scholar
• Zonder JA, Barlogie B, Durie BG, et al.Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006;108:403
   PubMed Web of Science ®Google Scholar
• Kanagasabaphy P, Morgan GJ, Davies FE. Proteasome inhibition and multiple myeloma. Curr Opin Investig Drugs 2007;8:447-51
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Soignet S, Dizon DS, et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced and solid tumor malignancies. Clin Cancer Res 2002;8:2505-11
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-27
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A Phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al. A Phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a Phase III trial in relapsed multiple myeloma; final time to event results of the APEX trial. Blood 2007;110(10):3557-60
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yang HH, Sadler K. Phase I – II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-44
   PubMed Web of Science ®Google Scholar
• Davies FE, WU P, Jenner MW, et al. The combination of cyclophosphamide, velcade and dexamethasone induces higher response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149-50
   PubMed Web of Science ®Google Scholar
• Reece DE, Piza GR, Trudel S, et al. A Phase I – II trial of bortezomib (Velcade) and oral cyclophosphamide plus prednisolone for relapsed/refractory multiple myeloma. Blood 2005;106:A2556
   Web of Science ®Google Scholar
• Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-37
   PubMed Web of Science ®Google Scholar
• Morris TCM, Drake M, Kettle PJ, et al. Bortezomib, adriamycin dexamethasone (PAD) combination therapies or patients with relapsed or refractory myeloma previously treated with VAD or VAD like therapy. Blood 2007;108:5117
   Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized Phase III study of pegyl ated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma; combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901
   PubMed Web of Science ®Google Scholar
• Palumbo AP, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisolone and thalidomide (VMPT) for relapsed multiple myeloma. Blood 2007;109:2767-72
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC. Velcade, doxil thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leuk Lymphoma 2005;46:1103-4
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S Avigan D, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter Phase I trial. Blood 2006;108:A405
   PubMed Web of Science ®Google Scholar
• Richardson PG, Chanan-Khan A, Lonial S, et al. A multicenter Phase I clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood 2006;108:A406
   Web of Science ®Google Scholar
• Richardson PG, Jakubowiak A, Wolf J, et al. A multicenter Phase I/II trial of perifosine (KRX-0401) alone and in combination with bortezomib in relapsed and refractory myeloma patients previously treated with bortezomib: preliniary results. Haematologica 2006;91:1498-505
   PubMed Web of Science ®Google Scholar
• Popat R, Williams C, Cook M, et al. A Phase I/II study of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. Blood 2006;108:A3542
   Google Scholar
• Zangari M, Barlogie B, Burns MJ, et al. VTD for advanced and refractory myeloma. Long term follow up of Phase I – II trial UARK-37. Superior outcomes in patients with normal cytogenetics and no T. Blood 2005;106:A716
   Google Scholar
• Hollmig K, Stover J, Talamo G, et al. VATD is an effective regimen in patients with relapsed or refractory myeloma. Blood 2004;104:2399
   Google Scholar
• Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM Phase II study. Haematologica 2006;91:1498-505
   PubMed Web of Science ®Google Scholar
• Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-62
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisolone in elderly untreated patients with multiple myeloma. Results of a multicentre Phase I/II study. Blood 2006;108:2165-72
   PubMed Web of Science ®Google Scholar
• Wang M, Giralt S, Delasalle K et al. Bortezomib in combination with thalidomide and dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235-9
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, Van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma; early results of total therapy 3. Br J Haematol 2007;138:176-85
   PubMed Web of Science ®Google Scholar